Dataset Information

Intermolecular Architecture of Fibrin Clots and its Interaction INterface with Albumin

ABSTRACT: In this project we establish the unit cell of fibrin polymer network by using of XL-MS methods and modelling approaches. With shotgun proteomics approach we estimate the ratio of proteins in the purified Fibrin Clots and ratio of Albumin inter- and intralinks

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Oleg Klykov

LAB HEAD: Albert J. R. Heck

PROVIDER: PXD011680 | Pride | 2020-01-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20180216_L1_Ag1_Klyko001_SA_F1_clots_Soluble_DSSO_SCX_frac1-8.raw	Raw
	20180216_L1_Ag1_Klyko001_SA_F1_clots_Soluble_DSSO_SCX_frac10.raw	Raw
	20180216_L1_Ag1_Klyko001_SA_F1_clots_Soluble_DSSO_SCX_frac11.raw	Raw
	20180216_L1_Ag1_Klyko001_SA_F1_clots_Soluble_DSSO_SCX_frac12.raw	Raw
	20180216_L1_Ag1_Klyko001_SA_F1_clots_Soluble_DSSO_SCX_frac13.raw	Raw

Items per page:

1 - 5 of 70

Publications

Missing regions within the molecular architecture of human fibrin clots structurally resolved by XL-MS and integrative structural modeling.

Klykov Oleg O van der Zwaan Carmen C Heck Albert J R AJR Meijer Alexander B AB Scheltema Richard A RA

Proceedings of the National Academy of Sciences of the United States of America 20200110 4

Upon activation, fibrinogen forms large fibrin biopolymers that coalesce into clots which assist in wound healing. Limited insights into their molecular architecture, due to the sheer size and the insoluble character of fibrin clots, have restricted our ability to develop novel treatments for clotting diseases. The, so far resolved, disparate structural details have provided insights into linear elongation; however, molecular details like the C-terminal domain of the α-chain, the heparin-binding ...[more]

PMID: 31924745

Similar Datasets

Project description:OBJECTIVE: To assess the safety and efficacy as well as determination of the molecular mechanism of action of topical allogeneic ADSC therapy in the treatment of ulcers in patients with neuropathic diabetic foot. RESEARCH DESIGN AND METHODS: We examined a total of 57 patients with neuropathic diabetic foot in grades IA and IIA according to the University of Texas classification. Finally 23 patients received treatment with standard therapy and fibrin glue (fibrin gel group) and 23 received treatment with standard therapy and ADSC suspended in tissue glue (fibrin gel + ADSC group). The primary outcome was determining the time needed to reduce the wound size by 50% from the initial size in both groups by assessing the wound surface, the evaluation of treatment safety, expressed as the occurrence of any adverse events; the evaluation of symptoms improvement (e.g. pain, itching, etc.) assessed by Visual Analogue Scale (VAS) and analysis of the expression of selected pro-angiogenic and immunomodulatory factors in the wounds treated in both study groups. RESULTS:The ADSC group benefited from the use of stem cells in terms of accelerated wound healing and greater likelihood of complete healing of the wound. In a second week after administration of therapy, the difference between the groups was already statistically significant (p = 0,04). The time to the 50% reduction of the size of the wound in the fibrin gel + ADSC group was significantly shorter (18.9 +/- 2.2 days ) than in the group receiving fibrin gel (39.8 +/- 6.9 days ), p = 0.0035. CONCLUSIONS: The results of the preliminary analysis show that the use of allogeneic ADSCs in the treatment of neuropathic diabetic foot ulcers is a safe method of therapy, which allows to improve the effects of wound healing. Our study indicates also the association of higher expression of selected proteins expression intensifying the healing process through a faster transition to the proliferation phase with a faster reduction in wound area, and long-term efficacy of allogeneic ADSC cells.